676 related articles for article (PubMed ID: 22267010)
21. Site-specific antibody-drug conjugation through an engineered glycotransferase and a chemically reactive sugar.
Zhu Z; Ramakrishnan B; Li J; Wang Y; Feng Y; Prabakaran P; Colantonio S; Dyba MA; Qasba PK; Dimitrov DS
MAbs; 2014; 6(5):1190-200. PubMed ID: 25517304
[TBL] [Abstract][Full Text] [Related]
22. Effect of attachment site on stability of cleavable antibody drug conjugates.
Dorywalska M; Strop P; Melton-Witt JA; Hasa-Moreno A; Farias SE; Galindo Casas M; Delaria K; Lui V; Poulsen K; Loo C; Krimm S; Bolton G; Moine L; Dushin R; Tran TT; Liu SH; Rickert M; Foletti D; Shelton DL; Pons J; Rajpal A
Bioconjug Chem; 2015 Apr; 26(4):650-9. PubMed ID: 25643134
[TBL] [Abstract][Full Text] [Related]
23. Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates.
Dennler P; Chiotellis A; Fischer E; Brégeon D; Belmant C; Gauthier L; Lhospice F; Romagne F; Schibli R
Bioconjug Chem; 2014 Mar; 25(3):569-78. PubMed ID: 24483299
[TBL] [Abstract][Full Text] [Related]
24. Long-term stabilization of maleimide-thiol conjugates.
Fontaine SD; Reid R; Robinson L; Ashley GW; Santi DV
Bioconjug Chem; 2015 Jan; 26(1):145-52. PubMed ID: 25494821
[TBL] [Abstract][Full Text] [Related]
25. Targeting HER2+ breast cancer cells: lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles.
Owen SC; Patel N; Logie J; Pan G; Persson H; Moffat J; Sidhu SS; Shoichet MS
J Control Release; 2013 Dec; 172(2):395-404. PubMed ID: 23880472
[TBL] [Abstract][Full Text] [Related]
26. Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates.
Burke PJ; Hamilton JZ; Jeffrey SC; Hunter JH; Doronina SO; Okeley NM; Miyamoto JB; Anderson ME; Stone IJ; Ulrich ML; Simmons JK; McKinney EE; Senter PD; Lyon RP
Mol Cancer Ther; 2017 Jan; 16(1):116-123. PubMed ID: 28062707
[TBL] [Abstract][Full Text] [Related]
27. Physicochemical stability of the antibody-drug conjugate Trastuzumab-DM1: changes due to modification and conjugation processes.
Wakankar AA; Feeney MB; Rivera J; Chen Y; Kim M; Sharma VK; Wang YJ
Bioconjug Chem; 2010 Sep; 21(9):1588-95. PubMed ID: 20698491
[TBL] [Abstract][Full Text] [Related]
28. Generation of therapeutic immunoconjugates via Residue-Specific Conjugation Technology (RESPECT) utilizing a native cysteine in the light chain framework of Oryctolagus cuniculus.
Albone EF; Spidel JL; Cheng X; Park YC; Jacob S; Milinichik AZ; Vaessen B; Butler J; Kline JB; Grasso L
Cancer Biol Ther; 2017 May; 18(5):347-357. PubMed ID: 28394698
[TBL] [Abstract][Full Text] [Related]
29. Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering.
Pillow TH; Tien J; Parsons-Reponte KL; Bhakta S; Li H; Staben LR; Li G; Chuh J; Fourie-O'Donohue A; Darwish M; Yip V; Liu L; Leipold DD; Su D; Wu E; Spencer SD; Shen BQ; Xu K; Kozak KR; Raab H; Vandlen R; Lewis Phillips GD; Scheller RH; Polakis P; Sliwkowski MX; Flygare JA; Junutula JR
J Med Chem; 2014 Oct; 57(19):7890-9. PubMed ID: 25191794
[TBL] [Abstract][Full Text] [Related]
30. Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs.
Junutula JR; Bhakta S; Raab H; Ervin KE; Eigenbrot C; Vandlen R; Scheller RH; Lowman HB
J Immunol Methods; 2008 Mar; 332(1-2):41-52. PubMed ID: 18230399
[TBL] [Abstract][Full Text] [Related]
31. Highly Potent, Anthracycline-based Antibody-Drug Conjugates Generated by Enzymatic, Site-specific Conjugation.
Stefan N; Gébleux R; Waldmeier L; Hell T; Escher M; Wolter FI; Grawunder U; Beerli RR
Mol Cancer Ther; 2017 May; 16(5):879-892. PubMed ID: 28258164
[TBL] [Abstract][Full Text] [Related]
32. Engineering THIOMABs for site-specific conjugation of thiol-reactive linkers.
Bhakta S; Raab H; Junutula JR
Methods Mol Biol; 2013; 1045():189-203. PubMed ID: 23913148
[TBL] [Abstract][Full Text] [Related]
33. In Vitro and In Vivo Evaluation of Cysteine Rebridged Trastuzumab-MMAE Antibody Drug Conjugates with Defined Drug-to-Antibody Ratios.
Bryant P; Pabst M; Badescu G; Bird M; McDowell W; Jamieson E; Swierkosz J; Jurlewicz K; Tommasi R; Henseleit K; Sheng X; Camper N; Manin A; Kozakowska K; Peciak K; Laurine E; Grygorash R; Kyle A; Morris D; Parekh V; Abhilash A; Choi JW; Edwards J; Frigerio M; Baker MP; Godwin A
Mol Pharm; 2015 Jun; 12(6):1872-9. PubMed ID: 25894424
[TBL] [Abstract][Full Text] [Related]
34. A Two-Step Immunocapture LC/MS/MS Assay for Plasma Stability and Payload Migration Assessment of Cysteine-Maleimide-Based Antibody Drug Conjugates.
Dong L; Li C; Locuson C; Chen S; Qian MG
Anal Chem; 2018 May; 90(10):5989-5994. PubMed ID: 29688004
[TBL] [Abstract][Full Text] [Related]
35. Determination of thiol-to-protein ratio and drug-to-antibody ratio by in-line size exclusion chromatography with post-column reaction.
Furuki K; Toyo'oka T
Anal Biochem; 2017 Jun; 527():33-44. PubMed ID: 28432000
[TBL] [Abstract][Full Text] [Related]
36. Assessment of physical stability of an antibody drug conjugate by higher order structure analysis: impact of thiol- maleimide chemistry.
Guo J; Kumar S; Prashad A; Starkey J; Singh SK
Pharm Res; 2014 Jul; 31(7):1710-23. PubMed ID: 24464270
[TBL] [Abstract][Full Text] [Related]
37. Identification of highly reactive cysteine residues at less exposed positions in the Fab constant region for site-specific conjugation.
Shiraishi Y; Muramoto T; Nagatomo K; Shinmi D; Honma E; Masuda K; Yamasaki M
Bioconjug Chem; 2015 Jun; 26(6):1032-40. PubMed ID: 25978737
[TBL] [Abstract][Full Text] [Related]
38. Conjugation of a reactive thiol at the nucleotide binding site for site-specific antibody functionalization.
Alves NJ; Mustafaoglu N; Bilgicer B
Bioconjug Chem; 2014 Jul; 25(7):1198-202. PubMed ID: 24932680
[TBL] [Abstract][Full Text] [Related]
39. Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates.
Lyon RP; Setter JR; Bovee TD; Doronina SO; Hunter JH; Anderson ME; Balasubramanian CL; Duniho SM; Leiske CI; Li F; Senter PD
Nat Biotechnol; 2014 Oct; 32(10):1059-62. PubMed ID: 25194818
[TBL] [Abstract][Full Text] [Related]
40. MAPN: First-in-Class Reagent for Kinetically Resolved Thiol-to-Thiol Conjugation.
Koniev O; Kolodych S; Baatarkhuu Z; Stojko J; Eberova J; Bonnefoy JY; Cianférani S; Van Dorsselaer A; Wagner A
Bioconjug Chem; 2015 Sep; 26(9):1863-7. PubMed ID: 26335849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
